- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01657318
Olivamine-containing Products in the Management of Patients With Nonhealing Lower Extremity Ulcers
August 12, 2018 updated by: Michael M. Lawenko MD, FPCS, De La Salle University Medical Center
A Prospective Observational Study on the Use of a Olivamine-containing Products in the Management of Patients With Compromised Nonhealing Lower Extremity Ulcers
In this study, the investigators hypothesize that the use of olivamine-containing products in the management of patients with compromised nonhealing lower extremity ulcers is feasible in the Philippine setting.
It will result in complete ulcer healing or wound closure after 16 weeks.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The specific aim of this study is to assess the feasibility of using olivamine-containing products in the management of patients with compromised nonhealing lower extremity ulcers in the Philippines.
The primary endpoint of which is to evaluate the efficacy of Olivamine on healing of chronic lower extremity ulcers which will be assessed by rate of change in ulcer size (wound healing trajectory) and proportion with complete ulcer healing (wound closure) at 4, 8, 16 and 16 weeks compared to baseline, week 0.
Study Type
Observational
Enrollment (Actual)
5
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Cavite
-
Dasmariñas, Cavite, Philippines, 4114
- De La Salle University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Potential study subjects will be patients who are 18 years or older, has confirmed with the informed consent.
He/she has a non-healing lower extremity ulcers compromised due to underlying factors such as peripheral arterial disease, diabetes, venous insufficiency, and pressure.
The ulcer must be between 1.0 cm2 and 10 cm2.
Description
Inclusion Criteria:
- Patient is 18 years old or older.
- Patient has a diagnosis of arterial, diabetic foot, venous insufficiency, or pressure ulcer or surgical and traumatic wound.
- Patient's target study ulcer/wound is a lower extremity full thickness ulcer/wound not involving tendon, capsule, or bone.
- Patient's target study ulcer/wound and is ≥1.0 cm2 and ≤ 10.0 cm2 in size at the day of initial consult.
- Study ulcer/wound has been present for greater than 6 weeks prior to initial consult.
- Patients with Charcot foot deformities can be entered so long as the Charcot disease is not active, and the ulcer can be offloaded by an orthotic device.
- The patient has adequate circulation to the lower extremity as evidenced by an ABI (measured by Doppler) of ≥ 0.7. If the patient has non-compressible leg arteries, as documented by an ABI >1.3, then the patient must have a Toe-Brachial Index be > 0.6, or a toe pressure >50 mm Hg.
- Patient must have adequate in-home support to comply with all protocol-mandated visits and procedures, offloading or pressure redistribution as required, and proper application of study products and wound care regimen.
- Patient or his/her legal representative has read and signed the Institutional Review Board-approved Informed Consent form before Screening.
Exclusion Criteria:
- An ulcer/wound that is ≥10.0 cm2 and ≤ 1.0 cm2 in size at the day of initial consult is not eligible for this study.
- Patient has clinical evidence of gangrene or infection on any part of the affected foot.
- The patient is judged by the investigator or study staff to be unable or unlikely to comply with daily wound care instructions, or study visits.
- Patient has clinical evidence of active sepsis or invasive infection (e.g., cellulitis, osteomyelitis).
- Patient has muscle, tendon, or bone exposure in any ulcer bed.
- Patient has known sensitivity or allergy to any component of the study product - Olivamine10.
- Patient has one or more medical condition(s), including renal, hepatic, hematologic, neurologic, or immune disease that in the opinion of the - Investigator would make the patient an inappropriate candidate for this wound healing study.
- Patient has a malignant disease (other than squamous or basal cell carcinoma of the skin) not in remission for five years or more.
- Patient has known alcohol or drug abuse.
- Patient has a hematocrit greater than 60% or less than 27%.
- Patient's diabetes is under poor control as manifested by HbA1c of >10.0%.
- Patient has clinically significant renal insufficiency or creatinine greater than 2.0 mg/dL.
- Patient has chronic liver disease or clinically significant liver enzyme abnormality as evidenced by elevated AST, ALT, or bilirubin greater than 1.5 times upper limit of normal (ULN).
- Patient is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents, or is anticipated to require such agents during the course of the study.
- Patient is using tobacco, or is exposed to a current smoker in their household. Patients may participate in the study if they have not used tobacco for 3 months and have not had a smoker in their household for 3 months.
- Patient is using any form of nicotine including nicotine patches, gums, or sprays.
- Patient has Acquired Immunodeficiency Syndrome (AIDS) or is known to be infected with Human Immunodeficiency Virus (HIV).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Chronic Wound Group
Treatment with Olivamine containing wound care products
|
Continuous wound care with Olivamine containing products until wound closure.
Intake of dietary supplement of 1 capsule for 60 days.
Other Names:
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Michael M Lawenko, MD, FPCS, De La Salle University Medical Center
- Study Chair: Melchor V. Frias, MD, De La Salle Health Sciences Institute
- Study Director: Renato CA Ocampe, MD, FPCS, De La Salle University Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 1, 2012
Primary Completion (ACTUAL)
January 30, 2013
Study Completion (ACTUAL)
February 15, 2013
Study Registration Dates
First Submitted
August 2, 2012
First Submitted That Met QC Criteria
August 3, 2012
First Posted (ESTIMATE)
August 6, 2012
Study Record Updates
Last Update Posted (ACTUAL)
August 14, 2018
Last Update Submitted That Met QC Criteria
August 12, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AKMRC-12-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Integra LifeSciences CorporationMayo Clinic; Temple University; Samuel Merritt University; New York College of... and other collaboratorsCompletedFoot Ulcers, DiabeticUnited States
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Diabetic Foot WoundsUnited States, Canada
-
HealthpointCompleted
Clinical Trials on Olivamine containing wound care products
-
Mahidol UniversityNational Research Council of ThailandTerminatedChildren | Wheat AllergyThailand
-
BSN Medical Ltd. UKTerminatedWound - in Medical CareUnited Kingdom
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedSoft Tissue InflammationUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingObesity | Malignant Breast Neoplasm | Body Mass Index Greater Than or Equal to 30 | Mammoplasty PatientUnited States
-
Siddhey LLCEnrolling by invitationWounds and Injuries | Burns | Trauma Injury | Venous Leg Ulcer | Degloving Injuries | Non-healing Wound | Mohs Surgery | Diabetic Foot Ulcer Mixed | Injury and WoundsUnited States
-
Huntleigh Healthcare LtdSerenaGroup, Inc.Completed
-
The University of Texas Health Science Center at...TerminatedCompartment Syndromes | WoundsUnited States
-
RedDress Ltd.CompletedNeuropathic Diabetic Ulcer - FootUnited States
-
University Hospital, CaenSociété de Dermatologie FrançaiseCompleted
-
Oystershell NVBioskin GmbHCompleted